Functional MRI-navigated Repetitive Transcranial Magnetic Stimulation over Supplementary Motor Area in Chronic Tic Disorders
Overview
Authors
Affiliations
Background: Open label studies have shown repetitive transcranial magnetic stimulation to be effective in reducing tics.
Objectives: To determine whether 8 sessions of continuous theta burst stimulation (cTBS) over supplementary motor area (SMA) given over 2 days may reduce tics and motor cortical network activity in Tourette syndrome/chronic tic disorders.
Methods: This was a randomized (1:1), double-blind, sham-controlled trial of functional MRI (fMRI)-navigated, 30 Hz cTBS at 90% of resting motor threshold (RMT) over SMA in 12 patients ages 10-22 years. Comorbid ADHD (n = 8), OCD (n = 8), and stable concurrent medications (n = 9) were permitted. Neuro-navigation utilized each individual's event-related fMRI signal. Primary clinical and cortical outcomes were: 1) Yale Global Tic Severity Scale (YGTSS) at one week; 2) fMRI event-related signal in SMA and primary motor cortex (M1) during a finger-tapping motor task.
Result: Baseline characteristics were not statistically different between groups (age, current tic/OCD/ADHD severities, tic-years, number of prior medication trials, RMT). Mean YGTSS scores decreased in both active (27.5 ± 7.4 to 23.2 ± 9.8) and sham (26.8 ± 4.8 to 21.7 ± 7.7) groups. However, no significant difference in video-based tic severity rating was detected between the two groups. Two-day post-treatment fMRI activation during finger tapping decreased significantly in active vs. sham groups for SMA (P = 0.02), left M1 (P = 0.0004), and right M1 (P < 0.0001). No serious adverse events occurred.
Conclusion: Active, fMRI-navigated cTBS administered in 8 sessions over 2 days to the SMA induced significant inhibition in the motor network (SMA, bilateral M1). However, both groups on average experienced tic reduction at 7 days. Larger sample size and protocol modifications may be needed to produce clinically significant tic reduction beyond placebo effect.
Aloufi A, Zahhar J, Bader M, Almutairi M, Alaaldeen A, Hetta O Front Psychiatry. 2025; 16:1478503.
PMID: 40041698 PMC: 11876145. DOI: 10.3389/fpsyt.2025.1478503.
Wang J, Yue J, Wang Y, Li X, Deng X, Lou Y CNS Neurosci Ther. 2025; 31(2):e70280.
PMID: 39981770 PMC: 11843473. DOI: 10.1111/cns.70280.
Targeting VMPFC-amygdala circuit with TMS in substance use disorder: A mechanistic framework.
Soleimani G, Conelea C, Kuplicki R, Opitz A, Lim K, Paulus M Addict Biol. 2025; 30(1):e70011.
PMID: 39783881 PMC: 11714170. DOI: 10.1111/adb.70011.
A critical role of action-related functional networks in Gilles de la Tourette syndrome.
Baldermann J, Petry-Schmelzer J, Schuller T, Mahfoud L, Brandt G, Dembek T Nat Commun. 2024; 15(1):10687.
PMID: 39681552 PMC: 11649905. DOI: 10.1038/s41467-024-55242-6.
Clinical neurophysiology in the treatment of movement disorders: IFCN handbook chapter.
Lefaucheur J, Moro E, Shirota Y, Ugawa Y, Grippe T, Chen R Clin Neurophysiol. 2024; 164:57-99.
PMID: 38852434 PMC: 11418354. DOI: 10.1016/j.clinph.2024.05.007.